Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2012

View Archived Issues

Resiniferatoxin improves urodynamic parameters in patients with overactive bladder

Solabegron demonstrates efficacy in phase II study

Long-term and post hoc phase III data presented on mirabegron

Ventana Medical Systems image analysis application cleared for use in U.S.

MorphoSys announces signing of protein engineering agreement

Affymax to receive milestone payment related to peginesatide

Watson Pharmaceuticals receives FDA complete response letter for vaginal gel

Ready-to-use oral therapy approved in China for oral mucositis in patients with cancer

Stem CentRx reports new APCDD1-binding antibodies

Bayer Schering Pharma patents novel potential anticancer agents

Novel antibacterials announced by Ranbaxy Laboratories

New aryl hydrocarbon receptor modulators developed in U.S.

New recombinant bacteria designed in Canada

Novartis identifies novel acetyl-CoA carboxylase 2 inhibitors

Study shows predictive value of PET/CT findings in retinoblastoma

Merck & Co. licenses Protein Sciences technology for vaccine research

Biodesix enters new collaboration

Advaxis reports data from first cohort in phase II ADXS-HPV trial

FDA grants priority review to Xarelto sNDA

Tranzyme Pharma and Norgine give update on ULISES 008 study

Two phase III cariprazine studies in schizophrenia meet primary endpoint

FDA grants fast track status to epicutaneous skin patch for peanut allergy

Apeiron begins study in prevention of radiation dermatitis

FDA grants Repros meeting to discuss Androxal development

Adocia's fast-acting human insulin comparable to NovoLog in phase IIa trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...